UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
The Company held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) on May 5, 2021. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:
Proposal 1: To elect the following director nominees to hold office until the 2022 Annual Meeting of Stockholders and until their respective successors are elected and qualified:
| For | Against | Abstain | Broker Non- Votes |
|||||||||||||
| Emily Peterson Alva |
231,387,113 | 3,503,246 | 24,437 | 18,156,126 | ||||||||||||
| J. Kevin Buchi |
196,515,957 | 35,282,932 | 3,115,907 | 18,156,126 | ||||||||||||
| Jeff George |
202,051,430 | 29,805,650 | 3,057,716 | 18,156,126 | ||||||||||||
| John Kiely |
195,800,930 | 36,058,602 | 3,055,264 | 18,156,126 | ||||||||||||
| Paul Meister |
206,606,442 | 25,255,223 | 3,053,131 | 18,156,126 | ||||||||||||
| Ted Nark |
211,039,400 | 20,820,472 | 3,054,924 | 18,156,126 | ||||||||||||
| Chintu Patel |
234,218,682 | 658,505 | 37,609 | 18,156,126 | ||||||||||||
| Chirag Patel |
234,094,799 | 787,783 | 32,214 | 18,156,126 | ||||||||||||
| Gautam Patel |
231,217,092 | 3,586,717 | 110,987 | 18,156,126 | ||||||||||||
| Shlomo Yanai |
234,425,336 | 450,144 | 39,316 | 18,156,126 | ||||||||||||
Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:
| For |
Against |
Abstain |
Broker Non- Votes | |||
| 233,858,559 |
881,197 | 175,040 | 18,156,126 |
Proposal 3: Approve an amendment to and restatement of the Amneal Pharmaceuticals, Inc. Certificate of Incorporation to remove references to the Company’s former Class B-1 common stock;
| For |
Against |
Abstain |
Broker Non- Votes | |||
| 252,305,563 |
248,527 | 516,832 | 0 |
Proposal 4: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021:
| For |
Against |
Abstain |
Broker Non- Votes | |||
| 252,745,819 |
269,437 | 55,666 | 0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 10, 2021 | AMNEAL PHARMACEUTICALS, INC. | |||||
| By: | /s/ Stephen J. Manzano | |||||
| Name: | Stephen J. Manzano | |||||
| Title: | Senior Vice President, General Counsel and Corporate Secretary | |||||
Document and Entity Information |
May 05, 2021 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0001723128 |
| Document Type | 8-K |
| Document Period End Date | May 05, 2021 |
| Entity Registrant Name | AMNEAL PHARMACEUTICALS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-38485 |
| Entity Tax Identification Number | 32-0546926 |
| Entity Address, Address Line One | 400 Crossing Blvd |
| Entity Address, City or Town | Bridgewater |
| Entity Address, State or Province | NJ |
| Entity Address, Postal Zip Code | 08807 |
| City Area Code | (908) |
| Local Phone Number | 947-3120 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Class A Common Stock, par value $0.01 per share |
| Trading Symbol | AMRX |
| Security Exchange Name | NYSE |
| Entity Emerging Growth Company | false |